Systemic antineoplastic therapy or radiotherapy within 14 days before the first dose of any study drug
Is expected to require any other form of antineoplastic therapy while on study.
Expected to require any other form of systemic or localized antineoplastic therapy while in this study
Is expected to require any non-protocol antineoplastic therapy while on study.
Is expected to require any other form of antineoplastic therapy while on study.
Is expected to require any other form of antineoplastic therapy while on study.
Other form(s) of antineoplastic therapy anticipated during the period of the study.
Expected to require any other form of systemic or localized antineoplastic therapy while on study
Expected to require any other form of systemic or localized anticancer therapy while on study.
Patient is expected to require any other form of systemic or localized antineoplastic therapy while on study
Is expected to require any other form of systemic or localized antineoplastic therapy while on trial (including maintenance therapy with another agent for NSCLC or radiation therapy)
Expected to require any other form of systemic antineoplastic therapy while receiving pembrolizumab
Is expected to require any other form of systemic or localized antineoplastic therapy while on study
Expected to require any other form of antineoplastic therapy while on study
Patient is expected to require any other form of systemic or localized antineoplastic therapy while on study
Patient is expected to require any other form of systemic or localized antineoplastic therapy while on study
Is expected to require any other form of systemic or localized antineoplastic therapy while on study (including maintenance therapy with another agent for NSCLC, radiation therapy, and/or surgical resection)
Systemic antineoplastic therapy
Is expected to require any other form of antineoplastic therapy while on study.
Subject is expected to require any other form of systemic or localized antineoplastic therapy while on study
Expected to require any other form of antineoplastic therapy while on study
Expected to require any other form of systemic or localized antineoplastic therapy during the study
Expected to require any other form of systemic or localized antineoplastic therapy while on trial
No other non-protocol antineoplastic agents will be permitted during this study
Patient is expected to require any other form of antineoplastic therapy while on study; including systemic chemotherapy, biological therapy, immunotherapy not specified in this protocol
Patient is expected to require any other form of systemic or localized antineoplastic therapy while on study
Patient is expected to require any other form of systemic or localized antineoplastic therapy while on study
Is expected to require any other form of antineoplastic therapy for SCLC, including radiation therapy, while on study. (Prophylactic cranial irradiation will be possible for those participants with stable disease or better at the completion of the 4 cycles of chemotherapy with or without pembrolizumab.)
Is expected to require any other form of antineoplastic therapy while on study
No systemic antineoplastic therapy may have been received between the time of biopsy and the first administration of study treatment.
Systemic antineoplastic therapy within 21 days before the first dose of study drug
Is expected to require any other form of systemic or localized antineoplastic therapy while on study
Subjects must not have received any form of systemic antineoplastic treatment for melanoma within the last year from day 1
Is expected to require any other form of antineoplastic therapy while participating in the trial
